At 5 µM for 16 hours, GW4869 reduced P100 extracellular-vesicle particles but increased P14 particles from SKBR3 and mouse L-cells. SKBR3 viability was maintained. These sedimentation-defined fractions overlap in size, so the findings support redistribution of vesicle release rather than uniform suppression of all extracellular vesicles. [2]
In B16F10 cells, free GW4869 had a weaker effect than the iron-containing HGF nanoformulation on CD63 and PD-L1 signals in a recovered exosome fraction. The evidence is a qualitative immunoblot comparison, not a particle-count inhibition measurement. HGF combines GW4869 with an iron-containing carrier, so its effects cannot be assigned to free GW4869 alone. [3]
Construct-dependent inhibition of human nSMase2
Biochemical assay · Human nSMase2 full-length WT/D430A and purified CAT/JX-CAT constructs [1]
GW4869 inhibited WT full-length enzyme and JX-CAT, whereas CAT and the residual activity of D430A constructs were insensitive. The pNPPC control was also insensitive.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response assays; 100 μM in the pNPPC control
- Method
- Radiolabeled sphingomyelin hydrolysis in Triton X-100 mixed micelles; parallel pNPPC hydrolysis control
- Reported limits
- Exact incubation time for each figure and GW4869 supplier, counterion, hydration and lot are not specified in the read methods. General methods distinguish cell-lysate from purified-protein incubation ranges; those ranges are not assigned as exact figure-specific times.
Methods and source locations
Compound reported in the paper: GW4869; Compound label in the paper: GW4869
Evidence concerns the named GW4869 material used by the authors. Counterion/hydration and equivalence to the current Adooq lot are not established; no mass-to-molar conversion is made.
Figs. 5E and 6A–D; Results: GW4869 Inhibition and the DK Switch; Methods: SMase Activity and Analysis of Catalytic Activity Using pNPPC
Full-length WT nSMase2 sphingomyelin hydrolysis: Concentration-response enzyme assay; D430A residual activity was not inhibited — Fig. 6D; GW4869 Inhibition and the DK Switch
Purified JX-CAT sphingomyelin hydrolysis: Construct comparison; CAT and JX-CAT D430A were not inhibited — Fig. 6C; GW4869 Inhibition and the DK Switch
CAT/JX-CAT pNPPC hydrolysis: Alternative soluble substrate; 100 μM GW4869 shown in Fig. 5E — Fig. 5E and caption; GW4869 Inhibition and the DK Switch
Opposite effects on operational EV fractions
Cell-based study · Human SKBR3 breast cancer cells; murine L-cells in Fig. 1b–c [2]
GW4869 reduced P100 particle concentrations but increased P14 particles. SKBR3 viability was maintained. Fractions overlap in size and cannot establish vesicle origin solely from sedimentation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 µM
- Exposure duration
- 16 hours (Fig. 1)
- Method
- Treatment in EV-free DMEM; differential EV fractionation followed by NTA and flow cytometry
- Vehicle
- DMSO control
- Reported limits
- Exact DMSO fraction, lot and counterion/hydration are not specified in the selected methods. Viability assay chemistry is not specified in the read scope.
Methods and source locations
Compound reported in the paper: GW4869; Compound label in the paper: GW4869
Evidence concerns the named GW4869 material used by the authors. Counterion/hydration and equivalence to the current Adooq lot are not established; no mass-to-molar conversion is made.
Fig. 1a–h; Fig. 2a–e; Results: GW4869 inhibition of nSMases differentially affects EV populations; Methods: Cell culture, Purification of MVs and Exos, Nanosight measurements, Flow cytometry
P100 and P14 EV particle concentrations: NTA; P14 increase additionally assessed by flow cytometry; normalized to cell number — Fig. 1b–g and caption; Fig. 2d–e
SKBR3 cell viability: Viability readout accompanying EV measurements; assay chemistry not specified in read scope — Fig. 1h; first Results subsection
Free GW4869 versus HGF in a recovered exosome fraction
Cell-based study · B16F10 mouse melanoma cells [3]
The recovered fraction showed a weaker effect with free GW4869 than with HGF on CD63 and PD-L1 immunoblot signals. HGF contains both GW4869 and iron in a hyaluronic-acid carrier; its response cannot be assigned to free drug alone.
Literature-Reported Treatment Conditions
- Treatment concentration
- 20 μM GW4869 in main-text exosome-isolation/Western-blot methods; SI Fig. 8 compares 0, 6.25, 12.5, 25 and 50 μM
- Method
- Recovered conditioned-medium fraction analyzed for CD63 and PD-L1 by Western blot; GAPDH used as loading control
- Vehicle
- PBS comparator; free-drug solvent not specified for Fig. 3a
- Co-treatment
- Free GW4869 compared with PBS, HACA-Fe and HGF (GW4869 plus iron-containing carrier)
- Reported limits
- Fig. 3a exposure duration and free-drug solvent are not specified in its direct isolation/blot methods. The adjacent 24-hour T-cell/exosome experiment is a distinct design and is not used to fill this gap. Salt, lot and catalog number are not specified.
Methods and source locations
Compound reported in the paper: GW4869; Compound label in the paper: GW4869
Evidence concerns the named GW4869 material used by the authors. Counterion/hydration and equivalence to the current Adooq lot are not established; no mass-to-molar conversion is made.
Fig. 3a; Supplementary Fig. 8 (SI physical page 5); Methods: Materials, Exosome isolation, Western blot analysis
CD63 and PD-L1 signals in recovered conditioned-medium fraction: Western blot; GAPDH loading control; representative of three experiments — Fig. 3a; Supplementary Fig. 8, SI physical page 5